Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33‐positive acute myeloid leukemia in first recurrence

Acute Myeloid Leukemia

1999 • 1,211 citations

Acute Myeloid Leukemia in the Elderly: Assessment of Multidrug Resistance (MDR1) and Cytogenetics Distinguishes Biologic Subgroups With Remarkably Distinct Responses to Standard Chemotherapy. A Southwest Oncology Group Study

1997 • 897 citations

Efficacy and Safety of Gemtuzumab Ozogamicin in Patients With CD33-Positive Acute Myeloid Leukemia in First Relapse

2001 • 877 citations

Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.

2001 • 821 citations

Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal Antibody (Rituximab, IDEC-C2B8)

1999 • 653 citations

Gemtuzumab Ozogamicin, A Potent and Selective Anti-CD33 Antibody−Calicheamicin Conjugate for Treatment of Acute Myeloid Leukemia

2001 • 551 citations

Hematopoietic Cell Transplantation

2000 • 514 citations

A randomized study of high-dose cytarabine in induction in acute myeloid leukemia [see comments]

1996 • 474 citations

Selective Ablation of Acute Myeloid Leukemia Using Antibody-Targeted Chemotherapy: A Phase I Study of an Anti-CD33 Calicheamicin Immunoconjugate

1999 • 458 citations

A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study

1996 • 423 citations

Selective Ablation of Acute Myeloid Leukemia Using Antibody-Targeted Chemotherapy: A Phase I Study of an Anti-CD33 Calicheamicin Immunoconjugate

1999 • 415 citations

A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study.

1992 • 373 citations

Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells

2001 • 332 citations

PRINCIPAL RESULTS OF THE MEDICAL RESEARCH COUNCIL'S 8th ACUTE MYELOID LEUKAEMIA TRIAL

1986 • 329 citations

Mylotarg? (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation

2001 • 278 citations

Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy

2002 • 240 citations

Expression of normal myeloid-associated antigens by acute leukemia cells

1986 • 227 citations

Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin)

2002 • 224 citations

Response to salvage therapy and survival after relapse in acute myelogenous leukemia.

1989 • 178 citations

THE USE OF RADIOLABELED ANTI-CD33 ANTIBODY TO AUGMENT MARROW IRRADIATION PRIOR TO MARROW TRANSPLANTATION FOR ACUTE MYELOGENOUS LEUKEMIA

1992 • 171 citations

Localization of radiolabeled antimyeloid antibodies in a human acute leukemia xenograft tumor model.

1992 • 114 citations

Definition of refractoriness against conventional chemotherapy in acute myeloid leukemia: a proposal based on the results of retreatment by thioguanine, cytosine arabinoside, and daunorubicin (TAD 9) in 150 patients with relapse after standardized first line therapy.

1990 • 114 citations

High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg®) treatment in acute myeloid leukemia patients

2004 • 110 citations

The Treatment of Acute Myeloid Leukemia in First Relapse: A Comprehensive Review of the Literature

2002 • 107 citations

Estimate of overall treatment results in acute nonlymphocytic leukemia based on age-specific rates of incidence and of complete remission.

1985 • 100 citations

Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomized comparison

1998 • 94 citations

Granulocyte–macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomized placebo-controlled trial (EMA91 Trial)

1999 • 77 citations

Duration of second complete remission in patients with acute myeloid leukemia treated with chemotherapy: a retrospective single-center study

1996 • 54 citations

The management of recurrent acute myelogenous leukaemia at a single centre over a fifteen‐year period

1993 • 41 citations

What is the best induction regimen for acute myelogenous leukemia?

1998 • 29 citations

Current status and perspectives of therapy for acute myeloid leukemia

2001 • 25 citations

Carboplatin infusion in relapsed and refractory acute myeloid leukemia--a Southwest Oncology Group trial.

1995 • 19 citations

Timed sequential chemotherapy for advanced acute myeloid leukemia

1996 • 19 citations